WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573966
CAS#: 910297-52-8 (N-oxide)
Description: Dasatinib N-oxide is a major metabolite of the Abl and Src kinase inhibitor Dasatinib. It is also a potential impurity in commercial preparations of dasatinib.
MedKoo Cat#: 573966
Name: Dasatinib N-oxide
CAS#: 910297-52-8 (N-oxide)
Chemical Formula: C22H26ClN7O3S
Exact Mass: 503.1506
Molecular Weight: 504.01
Elemental Analysis: C, 52.43; H, 5.20; Cl, 7.03; N, 19.45; O, 9.52; S, 6.36
Related CAS #: 863127-77-9 (hydrate) 302962-49-8 (free) 2112837-79-1 (cabaldehyde) 910297-52-8 (N-oxide)
Synonym: Dasatinib N-oxide
IUPAC/Chemical Name: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-4-oxido-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
InChi Key: UEFNEEZCTQCRAW-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H26ClN7O3S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(34-17)27-18-12-19(26-15(2)25-18)29-6-8-30(33,9-7-29)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
SMILES Code: OCCN(CCN1C2=CC(NC3=NC=C(C(NC4=C(Cl)C=CC=C4C)=O)S3)=NC(C)=N2)(CC1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 504.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Korashy HM, Rahman AF, Kassem MG. Dasatinib. Profiles Drug Subst Excip Relat Methodol. 2014;39:205-37. doi: 10.1016/B978-0-12-800173-8.00004-0. Review. PubMed PMID: 24794907.
2: Lindauer M, Hochhaus A. Dasatinib. Recent Results Cancer Res. 2014;201:27-65. doi: 10.1007/978-3-642-54490-3_2. Review. PubMed PMID: 24756784.
3: Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther. 2014 Mar 1;15(3):247-55. doi: 10.4161/cbt.27310. Epub 2013 Dec 18. Review. PubMed PMID: 24352048; PubMed Central PMCID: PMC3974824.
